Quoin Pharmaceuticals Files 8-K: Other Event
Ticker: QNRX · Form: 8-K · Filed: Dec 19, 2024 · CIK: 1671502
| Field | Detail |
|---|---|
| Company | Quoin Pharmaceuticals, Ltd. (QNRX) |
| Form Type | 8-K |
| Filed Date | Dec 19, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, other-event
TL;DR
Quoin Pharma filed an 8-K for an 'Other Event' - details TBD.
AI Summary
Quoin Pharmaceuticals, Ltd. filed an 8-K on December 19, 2024, reporting an "Other Event." The filing does not contain specific details about the event, its financial implications, or any associated dates beyond the filing date itself. The company was formerly known as Cellect Biotechnology Ltd. and Cellect Biomed Ltd.
Why It Matters
This 8-K filing indicates a significant event has occurred for Quoin Pharmaceuticals, but the lack of detail requires further investigation to understand its impact.
Risk Assessment
Risk Level: medium — The filing is an 8-K for an 'Other Event' without specific details, creating uncertainty about the nature and impact of the event.
Key Players & Entities
- Quoin Pharmaceuticals, Ltd. (company) — Registrant
- Cellect Biotechnology Ltd. (company) — Former name
- Cellect Biomed Ltd. (company) — Former name
- December 19, 2024 (date) — Filing date
FAQ
What specific event is Quoin Pharmaceuticals reporting in this 8-K filing?
The filing is categorized under 'Other Events' and does not provide specific details about the event itself.
When was the earliest event reported in this filing?
The earliest event reported is dated December 19, 2024, which is also the date of the report.
What were Quoin Pharmaceuticals' former names?
Quoin Pharmaceuticals was formerly known as Cellect Biotechnology Ltd. and Cellect Biomed Ltd.
What is Quoin Pharmaceuticals' principal executive office address?
The principal executive offices are located at 42127 Pleasant Forest Court, Ashburn, VA 20148-7349.
What is Quoin Pharmaceuticals' telephone number?
The registrant's telephone number, including area code, is (703) 980-4182.
Filing Stats: 957 words · 4 min read · ~3 pages · Grade level 13.8 · Accepted 2024-12-19 09:00:25
Filing Documents
- tm2431545d1_8k.htm (8-K) — 29KB
- 0001104659-24-130017.txt ( ) — 198KB
- qnrx-20241219.xsd (EX-101.SCH) — 3KB
- qnrx-20241219_lab.xml (EX-101.LAB) — 33KB
- qnrx-20241219_pre.xml (EX-101.PRE) — 22KB
- tm2431545d1_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. Quoin Pharmaceuticals Ltd. (the "Company" or "Quoin"), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, today announced FDA clearance to initiate a new additional Netherton Syndrome (NS) clinical study for QRX003. QRX003 is a topical lotion that contains a broad-spectrum serine protease inhibitor designed to target the kallikreins in the skin responsible for the excessive skin shedding associated with this disease. The study will be conducted by Dr. Amy Paller, of Northwestern University. It is planned that up to eight subjects will be enrolled into the study and will have QRX003 applied twice daily to greater than 80% of their entire body surface area (BSA) over a 12-week period. By comparison, in Quoin's ongoing open-label and double-blinded clinical studies, QRX003 is applied to approximately 20% of the represents the most extensive use of QRX003 in a clinical setting to date. It is anticipated that the data generated from this study will be used to supplement the data package to support the potential regulatory approval of QRX003 as a treatment for NS. Cautionary Note Regarding Forward Looking Statements The Company cautions that statements in this report that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as "expect," "intend," "plan," "anticipate," "believe," "look forward to," and "will," among others. All statements that reflect the Company's expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Date: December 19, 2024 QUOIN PHARMACEUTICALS LTD. By: /s/ Michael Myers Name: Dr. Michael Myers Title: Chief Executive Officer